RT Journal Article
SR Electronic
T1 Changes in performance status in continued smokers vs quitters after a diagnosis of lung cancer: a cohort study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 3064
DO 10.1183/13993003.congress-2020.3064
VO 56
IS suppl 64
A1 Lanyon, Kirsty
A1 Gemine, Rachel
A1 Davies, Gareth
A1 Lewis, Keir
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/3064.abstract
AB Introduction: We have recently shown that quitting smoking AFTER a diagnosis of lung cancer is associated with a reduction in mortality by 17% at 1 year(1). Our multi-site study (NCT01192256) now reports changes in Performance status (PS) in continued smokers versus quitter.Methods: Prospective, observational cohort study of 1134 patients in the UK with newly diagnosed non-small cell lung cancer. We recorded self-reported smoking status, validated with eCO(ppm) readings, at baseline and each follow-up visit until death for up to 2 years. PS was measured by the six-point Eastern Cooperative Oncology Group (ECOG) score.Cessation treatments were offered according to local services. Data was recorded on study case report forms and confirmed from hospital records and cancer databases. Missing data was removed at each time point and analysed with STATA.Results: 290 (25.6%) were smokers at baseline and 84 (29%) of these quit over the period.There were no differences in proportion of surviving people with each ECOG stage 0-3 between ‘Smokers’ and ‘Continuers’ at baseline (p=0.59), 1 month (p=0.67), 3 months (p=0.67), 6 months (p=0.32), 12 months (p=0.89) and 24 months (p=0.17).Conclusion: There were no differences in ECOG at any time point nor change form baseline between continued smokers versus quitters with NSCLC but numbers, especially over 2 years are very small.Our observational study continues with larger numbers (now more than 3000 at baseline) at each time point.1. Gemine, Rachel E., et al. Lung Cancer, 2019, Vol.129, p.1FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3064.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).